Does preoperative neutrophil-to-lymphocyte ratio have a value in predicting recurrence in bladder tumour after intravesical BCG treatment?

Camtosun A., Celik H., Altintas R., TOPÇU İ., TAŞDEMİR C.

BIOMEDICAL RESEARCH-INDIA, cilt.28, sa.1, ss.36-40, 2017 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 1
  • Basım Tarihi: 2017
  • Dergi Adı: BIOMEDICAL RESEARCH-INDIA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Chemical Abstracts Core
  • Sayfa Sayıları: ss.36-40
  • Anahtar Kelimeler: Cancer, Lymphocyte, BCG, Neutrophil, MPV, UROTHELIAL CARCINOMA, IMMUNE-RESPONSE, LUNG-CANCER, PROGRESSION, ADENOCARCINOMA, INFLAMMATION, BIOMARKERS, MORTALITY, THERAPY, BLOOD
  • İnönü Üniversitesi Adresli: Evet

Özet

The purpose of this study was to evaluate the prognostic value of the ratio of preoperative neutrophil to lymphocyte after intravesical BCG treatment in non-muscle invasive bladder cancer (NMIBC). The data of 89 patients, operated for urothelial carcinoma and treated with BCG after the diagnosis of NMIBC between 2007 and 2014, were reviewed retrospectively. Preoperative complete blood counts and first cystoscopic examination findings of the patients were examined. Median follow-up was 28.7 months. Tumour recurrence was detected in 33 patients (Group 2) of 89 patients. There was no tumour recurrence in 56 patients (Group 1). Neutrophil/lymphocyte ratio, MPV and CIS incidence were significantly increased in Group 2. This study showed that, preoperative high neutrophil/lymphocyte ratio, MPV and CIS occurrence can be used as independent criteria to predict tumour recurrence after intravesical BCG treatment in NMIBC.